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Abstract
A major obstacle to the development of effective treatment of Alzheimer’s disease (AD) is 
successfully delivery of drugs to the brain. We have previously identified a series of benzothiazole 
phosphonate compounds that block the interaction of amyloid beta peptide (Aβ) with amyloid-beta 
binding alcohol dehydrogenase (ABAD). A selective and sensitive method for the presence of 
three new benzothiazole ABAD inhibitors in mouse plasma, brain and artificial cerebrospinal fluid 
has been developed and validated based on high performance liquid chromatography tandem mass 
spectrometry. Mass spectra were generated using Micromass Quattro Ultima “triple” quadrupole 
mass spectrometer equipped with Electrospray ionization interface. Good linearity was obtained 
over a concentration range of 0.05–2.5 µg/ml. The lowest limit of quantification and detection was 
0.05µg/ml. All inter-day accuracies and precisions were within ±15% of the nominal value and 
±20%, respectively, at the lower limit of quantitation. The tested compounds were stable at 
various conditions with recoveries >90.0 % (RSD<10%). The method used for pharmacokinetic 
studies of compounds in mouse cerebrospinal fluid, plasma, and brain is accurate, precise, and 
specific with no matrix effect. Pharmacokinetic data showed these compounds penetrate the 
blood–brain barrier (BBB) yielding 4–50 ng/ml peak brain concentrations and 2 µg/ml peak 
plasma concentrations from a 10mg/kg dose. These results indicate that our newly synthesized 
small molecule ABAD inhibitor have good drug properties with the ability to cross the blood brain 
barrier, which holds a great potential for AD therapy.
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INTRODUCTION
Accumulation of the toxic amyloid-beta peptide (Aβ) in the brain is considered to be one of 
the primary causes for the Alzheimer’s disease (AD) pathogenesis. Mitochondria and 
synaptic dysfunction is an early pathological feature of AD affected brain [1–6], with Aβ 
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progressively accumulating in synaptic mitochondria and impairing mitochondrial structure 
and function including membrane potential, membrane permeability transition pore, 
respiration, energy metabolism, oxidative stress, mitochondrial dynamics, energy 
metabolism and calcium homeostasis [7–16]. Aβ binding alcohol dehydrogenase (ABAD) is 
a mitochondrial enzyme essential for metabolic function within the mitochondria [17–24]. 
Since Aβ forms a complex with ABAD, this enzyme has gained considerable interest as a 
potential target for AD treatment. More specifically, prevention and treatment of AD could 
perhaps be accomplished through the development of molecules that inhibit the formation of 
the Aβ-ABAD complex or compounds that block Aβ production.
Recent studies indicate that Aβ toxicity may be linked to the mitochondrial dysfunction 
present in AD [7, 15, 16, 25–29]. Through this interaction, Aβ is able to suppress normal 
ABAD enzymatic activity [30], while promoting oxidative stress[15, 25] and triggering a 
signal cascade resulting in apoptosis[15, 25]. Structural studies [15, 26] of this interaction 
show that introduction of Aβ results in a conformational change in ABAD preventing the 
binding of NAD+ and the loss of ABAD enzymatic activity. Targeted interruption of Aβ-
ABAD binding has been shown to suppress Aβ-induced neuronal dysfunction, which 
suggests that the Aβ-ABAD interaction is a prime target for novel AD treatment [22, 23]. 
The search has already started for inhibitors of this interaction with the most promising 
treatments being derived from the class of benzothiazolyl ureas [31].
Frentizole is a nontoxic antiviral and immunosuppressive benzothiazolyl urea drug [31], 
approved by the Food and Drug Administration (FDA) for rheumatoid arthritis and systemic 
lupus erythematosus. We identified frentizole as a novel inhibitor of the Aβ–ABAD 
interaction using ELISA-based screening assays for 45 benzothiazole urea compounds[31]. 
A novel benzothiazole urea with a 30-fold improvement in potency was identified from 
analysis of the frentizole structure–activity relationship (SAR) [31]. The SAR studies 
indicated that small electron-withdrawing groups were desirable as substituents on the 
benzothiazole ring and compounds with a hydroxyl group at the para position of the phenyl 
ring were particularly potent. In order for these compounds to readily penetrate the blood-
brain barrier (BBB) and enter the target organ [32–34], these compounds were converted to 
benzothiazole phosphonates. Since water solubility is essential, phosphate esters are 
frequently used as a prodrug strategy. The properties of xenobiotics can be enhanced in 
several ways by incorporating phosphate groups. Phosphate groups increase water solubility 
and thereby enable parenteral drug delivery. Phosphate groups can sometimes decrease the 
adverse effects of drugs and they can also provide significant and sustained delivery of the 
active drug species to the target organ by in vivo cleavage of the phosphonate carrier/drug 
linkage to provide a hydrophilic, negatively charged intermediate, which is ’locked’ in the 
brain or other organ[32–36]. Three potent benzothiazole phosphonate inhibitors of the 
ABAD-Aβ interaction (A1, A5 and A6) that bind to ABAD were identified using these 
criteria [37], they also rescued Aβ-mediated mitochondrial dysfunction [38]. These 
compounds are therefore potential therapeutic treatments for AD and their pharmacokinetic 
profile needs to be assessed. Currently, there are no data on the in vivo pharmacokinetic 
behavior of these compounds. Thus, there is a need to develop reliable analytical methods 
for evaluating the properties of these inhibitors. Liquid chromatography tandem mass 
Vangavaragu et al. Page 2













spectrometry (LC-MS/MS) is a proven method for the analysis of chemical compounds and 
can provide the low detection limits needed for compounds of interest.
The aim of this study is to validate a LC-MS/MS method of analysis with high sensitivity 
and reliability for the routine analysis of our compounds in mouse plasma and brain. Our 
objective is to build a pharmacokinetic profile and assess the ability of compounds A1, A5 
and A6 to cross the BBB in mice after intravenous administration.
MATERIALS AND METHODS
Chemical and reagents
Benzothiazole amino phosphonate derivatives were synthesized using a three-component 
reaction of equimolar quantities of aromatic aldehydes, 6-methoxybenzo[d]thiazol-2-amine, 
and dimethyl phosphate in toluene at reflux temperature in the presence of Mg (ClO4)2 [37]. 
In this study, we examined the three compounds that show better biological activity based 
on binding affinity and effect on mitochondrial function induced by calcium or Aβ [38]. 
Compounds A1, A5 and A6 were in the form of white powder characterized by melting 
points of 216 °C, 180 °C, 178 °C and exact masses of 453.0881 ± 0.0004 (n = 5) 0.1 ppm, 
395.0819 ± 0.0006 (n = 3) 3.0 ppm and 397.0788 ± 0.0012 (n = 3) 0.3 ppm, respectively. 
The molecular formula for A1, A5, and A6 are C19H22N2O7PS, C17H19N2O5PS, and 
C17H19FN2O4PS (Figure 1). The purity of the compounds was greater than 99% using 
HPLC. A sample of 800 nM concentration of each compound gave a chromatogram with S/
N>100 with was no other detectable peak. HPLC grade methanol, ethanol, formic acid, 
sodium chloride, potassium chloride, calcium chloride, magnesium chloride, HEPES, 
monosodium phosphate and sodium bicarbonate were purchased from Sigma (USA). A 
Millipore purification system (Labconco, Kansas City, MO, USA) was used to provide 
Millipore water.
Instrumentation—A Waters Acquity “classic” UPLC (Waters Corp USA) was used to 
develop CH3CN gradients on a C-18 reverse phase column. Column- effluent was 
introduced to the electrospray source of a Micromass Quattro Ultima “triple” quadrupole 
mass spectrometer (Micromass Ltd., Manchester, UK).
Methods
LC method for MS detection—Chromatographic separation was on an ACE C18 
column (Mac Mod Analytical, 3µm, Ultra-Inert HPLC Column, 50×2.1mm) protected by a 
matched ACE guard cartridge. Separation solvents were A: H2O (99%), methanol (1%) and 
formic acid (0.1%) and B: H2O (1%), methanol (99%) and formic acid (0.1%) delivered at a 
flow rate of 400 µl/min. The hydrophobic character of the analytes allows a large injection 
(50 µl) to chromatofocus on a column at 5% B. After 0.2 min, separation was with a linear 
gradient of 11% B/min for 4 min. Column wash was to 80% B for 2 min and re-equilibration 
at 5% B for 1.5 min for a total run-time of 8 min. The first 2 min of chromatographic 
effluent was diverted to waste.
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Mass spectrometry parameters—The mass spectrometer was run in positive ion mode 
using the electrospray ionization (ESI) source. The source block was 100°C and desolvation 
gas temperature 300°C. Argon collision gas pressure on a line to the cell was 1E-3 mbar. 
Quadrupoles 1 and 3 were set to 0.9 amu FWHH. Collision energy and cone voltage settings 
were optimized for each compound. The data were processed using MassLynx 4.1/
QuanLynx and Graphpad Prism 5. Fragmentation patterns of compounds A1, A5, and A6, 
methyl (Z)-3-(((6-methoxybenzo[d]thiazol-2-yl)imino)methyl)benzoate, 4-(1-((6-
methoxybenzo- [d]thiazol-2-yl) amino) ethyl) phenol and (Z)-1-(4-fluorophenyl)-N-(6-
methoxybenzo[d]thiazol-2-yl) methanimine were determined by infusing an aqueous/
methanol solution introduce with a T fitting into 30% solvent B from the UPLC for source 
optimization. The most abundant transitions were chosen for all the three compounds (Fig. 
1).
Preparation of calibration standards for recovery and quality controls—Stock 
solutions of A1, A5 & A6 and internal standards (IS) of 1mM in methanol were used to 
create calibration standards. Fifty microliters of IS (1µg/ml) plus 50 µl of calibration 
standard were diluted with 100 µl of water for a curve of nominal concentrations 0.05 to 2.5 
µg/ml to be injected onto the LC column. Quality control samples were prepared at nominal 
concentrations of low (0.05 µg/ml), medium (0.875 µg/ml), and high (2.5 µg/ml).
Preparation of calibration standards in matrices and quality controls samples
—Calibration standards were prepared by spiking into 50 µl of blank plasma, brain or 
artificial cerebrospinal fluid (ACSF) to yield final concentrations of 0.05 to 2.5 µg/ml. 
Quality control (QC) samples were prepared in the same manner at concentrations of 0.05, 
0.875 and 2.5 µg/ml for the low, medium and high level.
Sample preparation
ACSF Sample preparation: Due to the modest volume of CSF available from a mouse i.e., 
approximately 5 µl per mouse, we have selected an ACSF for development and calibration. 
The ACSF consists of 126 mM NaCl, 2.5 mM KCl, 20 mM HEPES, 1.2 mM NaH2PO4, 25 
mM NaHCO3, 2.4 mM CaCl2, and 1.2 mM MgCl2 at pH 7. Calibration points were 50µl of 
IS (1µg/ml), 50µl of calibration standard and the mixture then diluted with 100µl of ACSF, 
yielding final concentrations of IS (0.5 µg/ml) & standard sample (0.05–2.5 µg/ml) such that 
50% organic and 50% ACSF solution were injected onto the LC.
Plasma Sample preparation: Mouse plasma samples, 50 µl, were transferred to a 1.5 ml 
centrifuge tube and then 50 µL of IS (4 µg/ml) and 50µL of calibration standard sample were 
vortexed for 30 s. Acetonitrile (0.1ml) was added to precipitate the proteins. After being 
vortexed for 3min, the sample was centrifuged for 10min at 13000 rpm. Supernatant (50 µl) 
was diluted with 50 µl water and injected onto the column.
Brain Sample preparation: Brain tissue 100 mg was weighed and placed in a centrifuge 
tube. Methanol (100 µl) was added and homogenized for 1min before adding 100 µl IS (6 
µg/ml) to the homogenized mixture. The sample was vortexed for 30 s before centrifuging 
for 10 min at 13000 rpm. Then supernatant liquid was diluted 50% with water and injected.
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Method validation: The developed method was validated in terms of selectivity, linearity, 
lower limits of quantification (LLOQ), accuracy, precision, recovery, stability and matrix 
effects according to the FDA guidelines [39].
Accuracy and precision: Intra-day accuracy was calculated by using replicates (n = 5) of 
A1, A5 and A6 at three concentrations 0.05, 0.875 and 2.5 µg/ml of the spiked matrices 
during a single analytical session. The inter-day precision was also assessed by using 
replicates (n = 5) of three concentrations made on three separate days.
Stability: The stability of compounds A1, A5 and A6 was evaluated in ACSF, plasma and 
brain matrices under various temperature and storage conditions. Stability at room 
temperature was examined by analyzing samples at 25°C for 2 and 4 h and stability at 
−80°C was checked for one month. Samples were analyzed after three freeze-thaw cycles 
(−80°C to 25°C). Stability studies were performed at three concentrations.
Matrix effects assessment: Matrix effects were assessed with a post column infusion 
method. A pump infused each analyte at low concentration at a constant rate into a T fitting 
post column. The spectrometer was set to SRM mode for that target. Sample preparations, 
without analyte, were resolved on the LC column.
Extraction Recovery: The extraction recovery of each analysis was determined at the three 
concentrations low, mid and high (0.05, 0.875, and 2.5 µg/ml) using the non-dosed ACSF, 
plasma and brain samples. To determine the recovery, signals of spiked extracts from the 
blank ACSF, brain and plasma were compared with that of injection of pure standards in 
mobile phase. IS recovery was determined for a single concentration of 0.5 µg/ml.
Linearity and LLOQ: A calibration curve was prepared from a plot of the peak area ratio 
(y) of each analyte to IS against plasma concentration (x) using weighted (1/x) least squares 
regression analysis.
Application to pharmacokinetic study and data analysis: This study was performed in 
accordance with the recommendations in the Guide for the Care and Use of Laboratory 
Animals of the National Institutes of Health. Animal studies were approved by the Animal 
Care and Use Committee of University of Kansas in accordance with the National Institutes 
of Health guidelines for animal care. Using the validated LC-MS/MS method, blood and 
brain levels A1, A5 and A6 were measured in male and female C57BL6 mice (8-week-old, 
weighing approximately 25–30 g). The mice were housed in a room with controlled 
temperature (23 ± 3°C) and moisture level (55 ± 15% relative humidity) and exposed to a 
controlled 12 h light/12 h dark cycle. They were allowed to access to food and water ad 
libitum. Mice were fasted for 6h with free access to water prior to the pharmacokinetic 
study. To determine the time course of compounds A1, A5 and A6 action in the brain, we 
investigated the plasma pharmacokinetics and BBB penetration capability of the inhibitors. 
In these experiments, A1, A5 and A6 were administered to mice by intravenous injection at 
a dosage of 10 mg/kg. Blood and brain samples were collected from mouse at each time 
point (2, 5, 10, 30, 60, 120, 240, 360, 720, 1440 and 2880min), a total of 11 time points. For 
plasma measurements, blood (approximately 500–800 µl) was collected via cardiac–
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puncture into tubes containing sodium heparin anti-coagulant. Plasma was separated via 
centrifugation (4°C, 3500 rpm, 10 min) and stored in −80°C freezer. Qualitative 
confirmations of these compounds in CSF; samples were collected at 2 time points (240 and 
1440min) from five animals at each time points. At the time of measurement, frozen plasma 
samples were thawed at room temperature and vortexed thoroughly. The following 
quantities were estimates using non-compartmental calculations performed with 
WinNonlin™ 5.2 (Pharsight, Sunyvale, CA): 1) The area under the plasma concentration-
time curve during the period of observation (AUC0-t); 2) The area under the plasma 
concentration-time curve from zero to infinity (AUC0-∞); 3) The maximum plasma 
concentration (Cmax); 4) The time to reach Cmax(Tmax); and 5) The half-life (t1/2).
RESULTS
Method development
During the development of a detection method for analytes A1, A5 and A6, multiple 
solvents were tested to find the optimal mobile phase. Compounds A1, A5 and A6 dissolved 
partially in water, but dissolved readily in methanol or acetonitrile. Acetonitrile was selected 
for better peak shape and compatibility with serum/brain protein precipitation. A5 and A6 
were chosen as IS of A6, A1 and A5, respectively, because of their structural similarity. 
Selected reaction monitoring (SRM) acquisitions were used for sensitivity and extended 
dynamic range. The cone voltage and collision energy were optimized for A1, A5 and A6 
and the IS by continuously infusing a mixture of the two. The optimum cone voltage was 30 
V.
Matrix effects—There were no significant differences between the peaks generated by 
either the analytes extracted from the none-dosed ACSF, brain, and plasma or the analytes 
injected from water. The post-column infusion of 1 µg/ml A1, A5 or A6 showed no change 
of signal greater than 10% from sample matrix in their elution time windows.
Method validation
Selectivity—Selectivity was evaluated by analyzing non-dosed ACSF, brain, and plasma 
from three different mice. Individual samples were analyzed using LC-MS/MS conditions to 
prevent interference with A1, A5 and A6 as well as IS. No other endogenous peaks could be 
detected other than our analyte peaks, (Figure 2 & 3).
Linearity & LLOQ—The calibration curves were constructed by plotting the IS peak area 
ratio for analytes A1, A5 and A6 against the concentrations of the IS (A5 and A6). Each of 
the three calibrations curves (one for each matrix) were characterized by a linear segment 
and prepared in concentrations spanning 0.05–2.5 µg/ml. The regression equation for ACSF, 
plasma and brain for A1, A5 and A6 are listed in the (Table 1). Our LLOQ was 0.05 µg/ml 
from which a precision of < 10% RSD was observed.
Accuracy and precision—The intra-day and inter-day accuracy and precision values 
were determined after analyzing five replicates at three separate concentration levels (Table 
2). Intra-day accuracy for all three analytes ranged from 91.5% to 112.5% and contained a 
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RSD range of 0.36% to 9.24%. All samples analyzed maintained a variability of <10% 
(RSD) (Table 2). These results support the accuracy, reliability and reproducibility of our 
method.
Stability—The stability of ABAD compounds were determined under different temperature 
and storage conditions (Table 3). A1, A5 and A6 standards were dissolved in methanol and 
were subjected short-term exposure at 25°C for 2 and 4 h long-term storage conditions were 
assessed at −20°C for twenty days. The displayed variability across all samples was less 
than 10% (RSD).
Pharmacokinetic profile of compound A1, A5 and A6—The LC-MS/MS method 
described above was used for the determination of A1, A5 and A6 in plasma, brain, and CSF 
for pharmacokinetic study. This is the first time such a method has been developed and 
utilized for this purpose. Figure 4 illustrates the plasma concentration–time profiles of A1, 
A5 and A6 with intravenous administration. Based on the initial concentration data, the 
pharmacokinetic parameters including the area under the plasma concentration-time curve 
during the period of observation (AUC0-t), the area under the plasma concentration-time 
curve from zero to infinity (AUC0-∞) the maximum plasma concentration (Cmax), the time 
to reach Cmax (Tmax) and the half-life (t1/2) are shown in Table 4.
DISCUSSION
Molecular AD treatments need to cross the BBB to be effective. This restrictive membrane 
preserves the brain environment due to tight junctions between endothelial cells and 
transport mechanisms. It limits the access and distribution of molecules into the brain. 
Successful central nervous system (CNS) drugs have to cross the BBB, and this is often a 
limiting factor. Earlier studies in our laboratory have provided a series of small molecule 
benzothiazole phosphonates derivatives with low micromolar IC50 values against human 
ABAD [38]. These in vitro studies led us to choose the small molecule ABAD inhibitors 
(A1, A5 and A6) from this series for mouse pharmacokinetic studies. A detailed 
pharmacokinetics study of these new drugs candidates was therefore needed, and we have 
developed a new analytical LC–MS/MS approach to study the pharmacokinetic profiles of 
A1, A5 and A6 and describe it herein for mice plasma and brain samples after intravenous 
administration. The conditions for analysis and sample preparation were optimized, and the 
method was validated in terms of selectivity, sensitivity, accuracy, precision, and extraction 
recovery.
Pharmacokinetics provide new insights into the important role for understanding metabolism 
of drug action and is one of the most important techniques for elucidating the clinical 
efficacy or/and explaining and predicting a variety of events related to the efficacy [40–43]. 
The present study reveals a plasma and brain concentration–time curve for the three 
compounds. The detectable levels in brain suggested that the small molecule ABAD 
inhibitors (A1, A5 and A6) are able to cross the BBB.
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To the best of our knowledge, this is the first report to validate a new LC-MS/MS analytical 
procedure for evaluating the pharmacokinetics of small molecule ABAD inhibitors (A1, A5 
and A6) in mice. Our results clearly demonstrate that the LC–MS/MS method has excellent 
and satisfactory selectivity, sensitivity, linearity, precision, accuracy, and recovery. The 
separation of each analyte was conducted using a C-18 column along a methanol gradient. 
Each analyte was detected using tandem mass spectrometry-positive ion mode; followed by 
SRM experiments to observe the ions of each compound. Linearity was obtained using a 
concentration range of 0.05–2.5 µg/ml. The LLOQ and LLOD was 0.05 µg/ml. This specific 
and selective LC-MS/MS method was applied to a pharmacokinetic study after intravenous 
administration of A1, A5 and A6 and can be used in future pharmacokinetic studies. The 
compounds also efficiently cross the BBB and could therefore be effective AD drugs. The 
present in vivo pharmacokinetic studies of A1, A5 and A6 in mice provide valuable 
information for the systematic assessment and development of suitable dosage forms and 
clinical references concerning rational administration.
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Abbreviations
AD Alzheimer’s disease
ABAD Amyloid-beta binding alcohol dehydrogenase
Aβ Amyloid beta peptide
ACSF Artificial cerebrospinal fluid
BBB Blood Brain Barrier
CNS Central Nervous System
CSF Cerebrospinal fluid
ESI Electrospray ionization interface
FDA Food and Drug Administration
HPLC High-performance liquid chromatography
IS Internal standard
LC-MS/MS Liquid chromatography tandem mass spectrometry
LLOQ Lower Limit of quantification
LLOD Lower Limit of detection
QC Quality control
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SRM Selected reaction monitoring
UPLC Ultra Performance Liquid Chromatography
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Tandem mass spectrums of compounds A1 ([M+H]+ = 453), A5 ([M+H]+ = 395), & A6 ([M
+H]+ = 397), after activation of [M+H]+ at 30 V. The base peak fragments were the product 
ion used in SRM transitions. Cone voltage was 30 V.
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HPLC/SRM chromatograms of A1, A5 & A6 compounds; mouse CSF samples collected 
after 4h & 24h post intravenous injection of 10 mg/kg A1, A5 & A6, respectively. The 
representative chromatograms clearly shows that these three compounds when dosed 
individually penetrates the biological membrane i.e., BBB and enters the target organ. 
Sample preparation for 20µl of CSF was performed using 20µL of methanol (including 
1µg/ml IS), 50% organic and 50% aqueous solution.
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HPLC/SRM chromatograms of A1, A5 & A6 compounds; mouse brain samples collected at 
30min after intravenous injection of 10 mg/kg A1, A5 & A6, respectively. The 
representative chromatograms clearly shows that these three compounds when dosed 
individually penetrates the biological membrane i.e., BBB and enters the brain. Sample 
preparation for 100mg brain was performed using 200µl of 50/50 methanol/water (including 
6µg/ml IS).
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Mean plasma and brain concentration-time curves of compounds A1, A5 & A6 after 10 
mg/kg intravenous injection in mice. Each value is the mean ± SD of three determinations 
for brain (circles) and plasma (triangle).
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Table 1
Linear regression calibration equations from spiked ACSF, Plasma, Brain (n = 5) Area anlayte/Area internal 
standard.
Compound A1 Compound A5 Compound A6
ACSF
Day-1 y = 1.9104x+0.2883 (r2 = 0.9989) y = 4.2853x+0.3385 (r2 = 0.9987) y = 0.0274x+0.0346 (r2 = 0.9948)
Day-2 y = 1.859x+ 0.1983 (r2 = 0.9950) y = 4.7043x+0.1764 (r2 = 0.9936) y = 0.0277x+0.0395 (r2 = 0.9820)
Day-3 y = 1.8361x+0.1761 (r2 = 0.9919) y = 4.4399x+0.2693 (r2 = 0.9859) y = 0.0268x+0.0354 (r2 = 0.9839)
Plasma
Day-1 y = 6.8079x +0.6036 (r2 = 0.9808) y = 18.2874x+0.3274 (r2 = 0.9929) y = 19.2733x+0.3176 (r2 = 0.9968)
Day-2 y = 6.8628x +0.8166 (r2 = 0.9882) y = 17.9314x+0.0688 (r2 = 0.9941) y = 19.0504x+0.5253 (r2 = 0.9709)
Day-3 y = 6.9525x+0.9087 (r2 = 0.9854) y = 19.3519x+0.2756 (r2 = 0.9788) y = 19.3519x+0.2756 (r2 = 0.9788)
Brain
Day-1 y = 1.4924x +0.0471 (r2 = 0.9905) y = 5.0012x+0.0643 (r2 = 0.9922) y = 2.4517x+0.2544 (r2 = 0.9926)
Day-2 y = 1.5079x +0.3429 (r2 = 0.9975) y = 5.2436x+0.0597 (r2 = 0.9871) y = 2.7797x+0.3781 (r2 = 0.9915)
Day-3 y = 1.4983x +0.1586 (r2 = 0.9845) y = 5.1974x+0.0625 (r2 = 0.9918) y = 2.6885x+0.2814 (r2 = 0.9964)
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